Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients

CINCINNATI, Aug. 26, 2021.  Airway Therapeutics, Inc. (Airway), a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials